(NASDAQ: SEPN) Septerna's forecast annual revenue growth rate of -2.62% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.98%.
Septerna's revenue in 2026 is $72,255,000.On average, 11 Wall Street analysts forecast SEPN's revenue for 2026 to be $3,109,310,266, with the lowest SEPN revenue forecast at $0, and the highest SEPN revenue forecast at $5,490,199,919. On average, 11 Wall Street analysts forecast SEPN's revenue for 2027 to be $2,884,743,961, with the lowest SEPN revenue forecast at $0, and the highest SEPN revenue forecast at $5,395,541,300.
In 2028, SEPN is forecast to generate $3,103,450,447 in revenue, with the lowest revenue forecast at $1,546,090,782 and the highest revenue forecast at $4,259,637,869.